{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T14:39:43Z","timestamp":1784990383608,"version":"3.55.0"},"reference-count":38,"publisher":"Informa UK Limited","license":[{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/3.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["CEOR"],"DOI":"10.2147\/ceor.s302682","type":"journal-article","created":{"date-parts":[[2021,6,7]],"date-time":"2021-06-07T23:58:34Z","timestamp":1623110314000},"page":"465-473","source":"Crossref","is-referenced-by-count":22,"title":["Results of a Time and Motion Survey Regarding Subcutaneous versus Intravenous Administration of Daratumumab in Patients with Relapsed or Refractory Multiple Myeloma"],"prefix":"10.2147","volume":"Volume 13","author":[{"given":"Mary","family":"Slavcev","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allison","family":"Spinelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabeth","family":"Absalon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8061-3576","authenticated-orcid":true,"given":"Tara","family":"Masterson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Heuck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annette","family":"Lam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erwin","family":"De Cock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2021,6]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1111\/ejh.12790","volume":"97","author":"Ramsenthaler","year":"2016","journal-title":"Eur J Haematol"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"2789","DOI":"10.1007\/s00520-015-2644-6","volume":"23","author":"Baz","year":"2015","journal-title":"Support Care Cancer"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1186\/s12885-019-5467-x","volume":"19","author":"Parsons","year":"2019","journal-title":"BMC Cancer"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1080\/17474086.2019.1613886","volume":"12","author":"Seitzler","year":"2019","journal-title":"Expert Rev Hematol"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"6416378","DOI":"10.1155\/2018\/6416378","volume":"2018","author":"Szabo","year":"2018","journal-title":"Biomed Res Int"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"2516","DOI":"10.1182\/blood-2007-10-116129","volume":"111","author":"Kumar","year":"2008","journal-title":"Blood"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1177\/1060028013503122","volume":"47","author":"Barbee","year":"2013","journal-title":"Ann Pharmacother"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1182\/blood-2015-12-687749","volume":"128","author":"Krejcik","year":"2016","journal-title":"Blood"},{"key":"ref9","unstructured":"DARZALEX\u00ae (daratumumab) injection, for intravenous use [prescribing information]. Horsham, PA: Janssen Biotech, Inc; 2020."},{"key":"ref10","unstructured":"Darzalex (daratumumab) [summary of product characteristics]. Leiden, The Netherlands: Janssen Biologics BV; 2020."},{"key":"ref11","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1016\/S1470-2045(13)70383-8","volume":"14","author":"Pivot","year":"2013","journal-title":"Lancet Oncol"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"1913","DOI":"10.3324\/haematol.2017.173583","volume":"102","author":"Lugtenburg","year":"2017","journal-title":"Haematologica"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/S1470-2045(15)00447-7","volume":"17","author":"Rummel","year":"2016","journal-title":"Lancet Oncol"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1200\/JOP.18.00143","volume":"14","author":"Nooka","year":"2018","journal-title":"J Oncol Pract"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2019.243790","author":"San-Miguel","year":"2020","journal-title":"Haematologica"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1007\/s40262-016-0477-1","volume":"56","author":"Clemens","year":"2017","journal-title":"Clin Pharmacokinet"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1182\/blood.2019000667","volume":"134","author":"Usmani","year":"2019","journal-title":"Blood"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"e370","DOI":"10.1016\/S2352-3026(20)30070-3","volume":"7","author":"Mateos","year":"2020","journal-title":"Lancet Haematol"},{"key":"ref19","unstructured":"DARZALEX FASPROTM (daratumumab and hyaluronidase-fihj) injection, for subcutaneous use [prescribing information]. Horsham, PA: Janssen Biotech, Inc; 2020."},{"key":"ref20","doi-asserted-by":"publisher","first-page":"107","DOI":"10.3324\/haematol.2014.107714","volume":"100","author":"Blimark","year":"2015","journal-title":"Haematologica"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"234","DOI":"10.4274\/tjh.2013.0173","volume":"32","author":"Valkovic","year":"2015","journal-title":"Turk J Haematol"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"e552","DOI":"10.1200\/JOP.2016.019588","volume":"13","author":"Tai","year":"2017","journal-title":"J Oncol Pract"},{"key":"ref23","first-page":"334","volume":"22","author":"Lazaro Cebas","year":"2017","journal-title":"J BUON"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"S36","DOI":"10.1016\/j.jval.2018.04.303","volume":"21","author":"Fisher","year":"2018","journal-title":"Value Health"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"39","DOI":"10.2147\/PPA.S24752","volume":"6","author":"Barbosa","year":"2012","journal-title":"Patient Prefer Adherence"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/s40413-015-0075-y","volume":"8","author":"Price","year":"2015","journal-title":"World Allergy Organ J"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1016\/j.yebeh.2011.04.011","volume":"21","author":"Sweileh","year":"2011","journal-title":"Epilepsy Behav"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1007\/s12325-010-0108-4","volume":"28","author":"Small","year":"2011","journal-title":"Adv Ther"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1188\/13.CJON.S2.25-32","volume":"17","author":"Kurtin","year":"2013","journal-title":"Clin J Oncol Nurs"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1007\/s00520-012-1615-4","volume":"21","author":"Armoogum","year":"2013","journal-title":"Support Care Cancer"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1007\/s00520-009-0793-1","volume":"19","author":"Molassiotis","year":"2011","journal-title":"Support Care Cancer"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1002\/pon.1670","volume":"19","author":"Stenberg","year":"2010","journal-title":"Psychooncology"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1200\/JOP.0723601","volume":"3","author":"Erikson","year":"2007","journal-title":"J Oncol Pract"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"3550","DOI":"10.1182\/bloodadvances.2019000307","volume":"3","author":"Sharma","year":"2019","journal-title":"Blood Adv"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1504\/IJBHR.2011.043414","volume":"2","author":"Rosenman","year":"2011","journal-title":"Int J Behav Healthc Res"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"e0157957","DOI":"10.1371\/journal.pone.0157957","volume":"11","author":"De Cock","year":"2016","journal-title":"PLoS One"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"2495","DOI":"10.1038\/s41375-018-0120-2","volume":"32","author":"Barr","year":"2018","journal-title":"Leukemia"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1002\/cam4.573","volume":"5","author":"De Cock","year":"2016","journal-title":"Cancer Med"}],"container-title":["ClinicoEconomics and Outcomes Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.dovepress.com\/getfile.php?fileID=70299","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.dovepress.com\/getfile.php?fileID=70299","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,7]],"date-time":"2021-06-07T23:58:38Z","timestamp":1623110318000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.dovepress.com\/results-of-a-time-and-motion-survey-regarding-subcutaneous-versus-intr-peer-reviewed-fulltext-article-CEOR"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6]]},"references-count":38,"URL":"https:\/\/doi.org\/10.2147\/ceor.s302682","relation":{},"ISSN":["1178-6981"],"issn-type":[{"value":"1178-6981","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6]]}}}